WO2010040083A3 - Prédicteurs de chimiorésistance par expression génique - Google Patents

Prédicteurs de chimiorésistance par expression génique Download PDF

Info

Publication number
WO2010040083A3
WO2010040083A3 PCT/US2009/059423 US2009059423W WO2010040083A3 WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3 US 2009059423 W US2009059423 W US 2009059423W WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
chemotherapeutic agent
methods
chemoresistance
gene expression
Prior art date
Application number
PCT/US2009/059423
Other languages
English (en)
Other versions
WO2010040083A2 (fr
Inventor
Jeffrey E. Green
Hark K. Kim
Original Assignee
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A., As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A., As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2010040083A2 publication Critical patent/WO2010040083A2/fr
Publication of WO2010040083A3 publication Critical patent/WO2010040083A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention concerne des signatures génétiques décrivant des profils génétiques. Les signatures génétiques peuvent prédire si un sujet atteint d'un cancer, tel qu'un cancer de l'estomac, sera chimiorésistant ou chimiosensible à une chimiothérapie à base de cisplatine et de fluorouracile. L'invention décrit ainsi des méthodes permettant de déterminer si un sujet atteint d'un cancer sera sensible à un traitement avec un agent chimiothérapeutique. L'invention décrit des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si EGFR, FGFR-2 et MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique. L'invention décrit également des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si un ou plusieurs marqueurs de cellules souches embryonnaires ou une ou plusieurs cibles MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique.
PCT/US2009/059423 2008-10-03 2009-10-02 Prédicteurs de chimiorésistance par expression génique WO2010040083A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19512308P 2008-10-03 2008-10-03
US61/195,123 2008-10-03
US17839209P 2009-05-14 2009-05-14
US61/178,392 2009-05-14

Publications (2)

Publication Number Publication Date
WO2010040083A2 WO2010040083A2 (fr) 2010-04-08
WO2010040083A3 true WO2010040083A3 (fr) 2010-06-24

Family

ID=41506489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059423 WO2010040083A2 (fr) 2008-10-03 2009-10-02 Prédicteurs de chimiorésistance par expression génique

Country Status (1)

Country Link
WO (1) WO2010040083A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107254546B (zh) * 2017-08-16 2020-11-03 复旦大学附属华山医院 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569012A4 (fr) 2010-05-11 2013-10-30 Aveo Pharmaceuticals Inc Anticorps anti-fgfr2
CA2811015A1 (fr) 2010-09-15 2012-03-22 Almac Diagnostics Limited Test de diagnostic moleculaire du cancer
WO2013071502A1 (fr) * 2011-11-17 2013-05-23 Genedia Biotech Co Ltd Gène mir-193a-3p et gènes associés prédisant la tumorigenèse et les résultats d'une chimiothérapie
WO2014018683A2 (fr) * 2012-07-24 2014-01-30 Cedars-Sinai Medical Center Nouvelle méthode de détection de la résistance à la chimiothérapie chez des patients atteints d'un cancer du poumon
EP2695950A1 (fr) * 2012-08-10 2014-02-12 Blackfield AG Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes
GB201316027D0 (en) * 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for oesophageal cancer
JP7113842B2 (ja) * 2017-03-29 2022-08-05 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 胃がんのセツキシマブ感受性を決定するためのシステムおよび方法
CN111057762B (zh) * 2019-11-28 2022-11-08 中国人民解放军陆军军医大学第一附属医院 检测基因在制备检测食管鳞癌对顺铂敏感性的制剂中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037088A1 (en) * 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037088A1 (en) * 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"[HG-U133A] Affymetrix Human Genome U133A Array", GEO,, 11 March 2002 (2002-03-11), XP002527544 *
H. K. KIM, I. J. CHOI, C. G. KIM, A. OSHIMA AND J. E. GREEN: "Gene expression signatures to predict the response of gastric cancer to cisplatin and fluorouracil", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15s, 20 May 2009 (2009-05-20), pages 4628, XP002565666, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4628> [retrieved on 20100127] *
HAMILTON ET AL: "A Review of the Genomics of Gastric Cancer", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 4, no. 4, 1 April 2006 (2006-04-01), pages 416 - 425, XP005367985, ISSN: 1542-3565 *
HSU DAVID S ET AL: "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 28, 1 October 2007 (2007-10-01), pages 4350 - 4357, XP002513951, ISSN: 0732-183X *
KIHARA C ET AL: "Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 61, no. 17, 1 September 2001 (2001-09-01), pages 6474 - 6479, XP002960719, ISSN: 0008-5472 *
KNECHT RAINALD ET AL: "EGFR antibody-supplemented TPF-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6C, 1 November 2003 (2003-11-01), pages 4789 - 4795, XP009128280, ISSN: 0250-7005 *
METZGER R ET AL: "ERCC1 MRNA LEVELS COMPLEMENT THYMIDYLATE SYNTHASE MRNA LEVELS IN PREDICTING RESPONSE AND SURVIVAL FOR GASTRIC CANCER PATIENTS RECEIVING COMBINATION CISPLATIN AND FLUOROURACIL CHEMOTHERAPY", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 16, no. 1, 1 January 1998 (1998-01-01), pages 309 - 316, XP001118953, ISSN: 0732-183X *
NAPIERALSKI RUDOLF ET AL: "Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 8, 15 April 2005 (2005-04-15), pages 3025 - 3031, XP002551877, ISSN: 1078-0432 *
NISHIMURA T ET AL: "Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.", CLINICAL CANCAR RESEARCH, vol. 2, 1 November 1996 (1996-11-01), pages 1859 - 1865, XP002565665 *
ROTOLO SABRINA ET AL: "Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells", PLOS ONE, vol. 3, no. 6, June 2008 (2008-06-01), XP002565668, ISSN: 1932-6203 *
STEWART ET AL: "Mechanisms of resistance to cisplatin and carboplatin", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 63, no. 1, 1 July 2007 (2007-07-01), pages 12 - 31, XP025320373, ISSN: 1040-8428, [retrieved on 20070528] *
WANG W., ET AL: "Establishment and biological characteristics of a multi-drug resistant cell line A549/Gem", CHIN J LUNG CANCER, vol. 11, no. 1, February 2008 (2008-02-01), pages 55 - 61, XP002565667, Retrieved from the Internet <URL:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path%5B%5D=16&path%5B%5D=20> [retrieved on 20100128], DOI: 10.3779/j.issn.1009-3419.2008.01.014 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107254546B (zh) * 2017-08-16 2020-11-03 复旦大学附属华山医院 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用

Also Published As

Publication number Publication date
WO2010040083A2 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2010040083A3 (fr) Prédicteurs de chimiorésistance par expression génique
MX2010005960A (es) Biomarcadores de braf.
WO2008094678A3 (fr) Signature pronostique moléculaire pour prédire des métastases distantes chez les femmes atteintes d&#39;un cancer du sein, et ses utilisations
WO2009037572A3 (fr) Combinaisons de bio-marqueurs du cancer colorectal
WO2010096154A3 (fr) Compositions et méthodes de diagnostic et de pronostic de cancer colorectal
WO2010009337A3 (fr) Signatures et déterminants de la pc associés au cancer de la prostate et leurs procédés d’utilisation
WO2007082144A3 (fr) Methode permettant de detecter un cancer a l&#39;aide de b7-h1 et de survivine
WO2011153254A3 (fr) Biomarqueurs d&#39;acides nucléiques circulants associés au cancer de la prostate
EP2524059A4 (fr) Détection d&#39;affections gastro-intestinales
WO2013106844A3 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer du pancréas
WO2012021887A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
MX340453B (es) Biomarcadores para cancer de pulmon.
EP3543360A3 (fr) Détection de néoplasme
GB2507458A (en) Automated detection of flaws and incompatibility problems in information flow downgraders
WO2012068400A3 (fr) Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
EP2276509A4 (fr) Détection et traitement du cancer du pancréas, des ovaires et d&#39;autres cancers
WO2011082198A3 (fr) Biomarqueurs du cancer permettant de prédire la récurrence et le potentiel métastasique
WO2009038754A3 (fr) Signatures de l&#39;expression génique dans des échantillons de cellules tumorales enrichis
WO2012074904A3 (fr) Procédés et systèmes pour l&#39;évaluation de la sensibilité ou de la résistance des échantillons tumoraux vis-à-vis d&#39;agents chimio-thérapeutiques
WO2013057581A3 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
EP2611941A4 (fr) Signatures génétiques pour le diagnostic et le pronostic du cancer
WO2010120942A3 (fr) Modèles de modification des histones utilisables à des fins de diagnostic clinique et de pronostic en matière de cancer
WO2009094647A3 (fr) Biomarqueurs p53
NZ629555A (en) Monocyte biomarkers for cancer detection
WO2009055823A3 (fr) Procédé permettant de prédire la réactivité du cancer de la poitrine à une chimiothérapie de type polyamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793289

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09793289

Country of ref document: EP

Kind code of ref document: A2